Canada: Pharma In Brief - Federal Court Of Appeal Overturns Federal Court Decision And Dismisses Application For Prohibition Order

Case: Pharmascience Inc. v AstraZeneca Canada Inc. et al 2014 FCA 133
Nature of case: Appeal of a s.6 prohibition order pursuant to the PM(NOC) Regulations
Date of decision: May 22, 2014 (public reasons available as of June 10, 2014)

Summary

Pharmascience Inc. (Pharmascience) appealed from the decision of Justice O'Keefe of the Federal Court (reported as AstraZeneca Canada Inc. v. Pharmascience Inc., 2012 FC 1189) prohibiting the Minister of Health from issuing a Notice of Compliance to Pharmascience for its version of the drug omeprazole formulated using low viscosity hydroxypropylmethylcellulose (HPMC).

The appeal was allowed and the application for a prohibition order was dismissed. This decision is notable in that it specifies that evidence going beyond the mere fact of detailing an allegation of invalidity in a notice of allegation has to be adduced by a respondent to properly put this allegation "into play". The decision further defines that the legal standard that has to be met by an applicant in response to an allegation of lack of utility is "proof on the balance of probabilities" that the invention is useful.

By way of background, AstraZeneca Canada Inc. (AstraZeneca) brought an application for prohibition in response to Pharmascience's notice of allegation which claimed that Canadian Patent No. 2,290,531 ('531 Patent) was invalid on a number of grounds including lack of utility and obviousness. The Federal Court of Appeal held that the application judge erred in law with respect to both the legal standard to be met by Pharmascience in order to "put its allegations into play", and the legal standard AstraZeneca was required to meet to prove that its invention was useful. Upon review of the evidence, the Court of Appeal concluded that the evidence adduced by Pharmascience was sufficient to put its allegation of lack of utility into play and that in response, AstraZeneca had not satisfied its onus of showing on a balance of probabilities that the allegation of invalidity of the '531 Patent was not justified.

Analysis

Trial decision

At trial, Pharmascience submitted that the '531 Patent did not indicate that any tests were performed to demonstrate that low viscosity HPMC actually possessed the claimed utility, and no substantive data was provided to demonstrate the promised utility. In this regard, the application judge found that since the allegation of lack of utility was raised in its Notice of Allegation, Pharmascience has met its evidentiary burden of putting this allegation "into play" and therefore that the burden of proof rested on AstraZeneca to establish that it was not justified.

AstraZeneca for its part pointed to the statement in the patent that "results from a number of experiments with different batches of HPMC indicate that HPMC with a cloud point of at least 45.6° C is desirable in fulfilling the regulatory requirements on rate of release of omeprazole." The Federal Court found that such a statement was sufficient to meet its burden for proving utility. Even though this evidence was recognized by the application judge as being "relatively non-descriptive", it was nonetheless held that AstraZeneca should not have to meet a higher burden.

As a result, the application judge found that Pharmascience had failed to demonstrate that the invention did not work at all or did not do what the specification promised it would do. It was thus concluded that AstraZeneca had shown that Pharmascience's allegations of lack of utility were not justified.

Court of Appeal decision

The Court of Appeal limited its discussion to the issue of utility.  The Court began its analysis with the note that "due to the peculiar nature of notice of compliance proceedings, the issue of the onus of proof has been the subject of considerable discussion in the jurisprudence." According to the Court of Appeal, such peculiarity is due to the fact that the applicant for an order of prohibition must necessarily respond to the respondent's notice of allegation, and therefore show that the allegations therein are not justified. However, because of the presumption of validity set out at subsection 43(2) of the Patent Act, the jurisprudence has held that the respondent still has the onus of putting these allegations "into play".

The Court of Appeal reviewed some of the jurisprudence on that issue which has held that the respondent must prove its allegations on a "balance of probabilities" standard, while other cases have held that the respondent must simply lead sufficient evidence to give its allegations "an air of reality". It then confirmed that Pharmascience, as the respondent in prohibition proceedings, had the onus of leading evidence sufficient to put its allegations of invalidity "into play" which contrary to the view of the application judge, cannot be satisfied by the mere fact of detailing its allegation of invalidity of the patent for lack of utility in its notice of allegation.

Furthermore, the Court of Appeal held that for AstraZeneca to meet its burden of proving utility, it has to adduce evidence at a "higher burden", which corresponds to proof on the balance of probabilities. This burden cannot be met by reference in the patent to a relatively non-descriptive statement, as was accepted by the trial judge.  

In its assessment, the Court of Appeal held that the application judge erred in law with respect to the type of evidence that had to be adduced by Pharmascience in order to put its allegations into play, and the legal standard AstraZeneca was required to meet to prove that its invention was useful.

Due to these errors, the Court of Appeal found that the application judge did not properly construe the evidence that Pharmascience had to put forward to put its allegation of lack of utility into play and further failed to assess whether AstraZeneca showed, on the correct standard of "balance of probabilities", that Pharmascience's allegations of lack of utility were not justified. The Court of Appeal accordingly undertook to do this analysis as at first instance.

Pharmascience's expert criticized AstraZeneca's test results aimed at proving utility of the invention in the '531 Patent, given that the applicable protocol did not indicate the number of samples tested and the number of studies conducted for each type of HPMC were not known. He also criticized the validity of the statistical test results as being insufficient, in and of themselves, to prove that the release of omeprazole is directly and consistently related to the cloud point of the batch of low viscosity HPMC used in the formulation of an oral dosage form of omeprazole. The Court considered these comments as sufficient to put the allegation of lack of utility "into play".

AstraZeneca's expert's evidence was considered by the Court of Appeal as non-responsive to the real issue raised by Pharmascience's expert. The expert was unable to state how many samples were tested and what the individual results were.  It was therefore impossible for the Court to assess the significance of these results. Without being able to assess the results, the Court held it was impossible to determine whether the experiments actually proved that which the inventors claimed they proved.

Since the patent did not provide that information and no expert supplied it, the Court concluded that there was no evidence before the Court capable of establishing that low viscosity HPMC with a cloud point equal to or higher than that described in the '531 patent will consistently result in release rates in excess of the regulatory standard, as promised by the invention. The Court of Appeal thus concluded that AstraZeneca had not satisfied the onus of showing on a balance of probabilities that Pharmascience's allegations of invalidity were not justified.

Link to decisions

Pharmascience Inc. v. Canada (Health), 2014 FCA 133

AstraZeneca Canada Inc. v. Pharmascience Inc., 2012 FC 1189

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions